Skip to main content
Top
Published in: Rheumatology International 7/2006

01-05-2006 | Original Article

Antioxidant status, lipid peroxidation and nitric oxide in fibromyalgia: etiologic and therapeutic concerns

Authors: Salih Ozgocmen, Huseyin Ozyurt, Sadik Sogut, Omer Akyol, Ozge Ardicoglu, Hulya Yildizhan

Published in: Rheumatology International | Issue 7/2006

Login to get access

Abstract

We proposed to assess the oxidant/antioxidant status, lipid peroxidation and nitric oxide (NO) in untreated fibromyalgia (FM) patients and controls. The effect of amitriptyline (A, 20 mg daily) and sertraline (S, 100 mg daily) treatment on patients’ superoxide dismutase (SOD), xanthine oxidase (XO), adenosine deaminase (ADA) enzyme activities, thiobarbituric acid reactive substances (TBARS) and NO levels was investigated. Thirty female patients with primary FM and age-matched 16 healthy female controls were included. Patients received an 8-week course of treatment with either A or S. FM patients had higher serum levels of TBARS (particularly malondialdehyde) and lower levels of nitrite compared to controls whereas enzyme activities were similar. A and S significantly improved Fibromyalgia Impact Questionnaire (FIQ) pain scores, Hamilton anxiety and depression rating scales. But neither A nor S had significant effects on measured oxidative stress parameters, except SOD activity that was significantly reduced after S treatment. Total myalgic scores negatively correlated with XO activity, and depression scales negatively correlated with levels of TBARS. Our results indicate that patients with FM are under oxidative stress. These findings represent a rationale for further research assessing the effect of free radical scavengers or antioxidant agents like vitamins and omega-3 fatty acids on peripheral and central mechanisms in FM.
Literature
1.
go back to reference Goldenberg DL (1999) Fibromyalgia syndrome a decade later. What have we learned? Arch Intern Med 159:777–785CrossRefPubMed Goldenberg DL (1999) Fibromyalgia syndrome a decade later. What have we learned? Arch Intern Med 159:777–785CrossRefPubMed
2.
go back to reference Cofford LJ, Appleton BE (2000) The treatment of fibromyalgia: a review of clinical trials. Curr Rheum Rep 2:101–103CrossRef Cofford LJ, Appleton BE (2000) The treatment of fibromyalgia: a review of clinical trials. Curr Rheum Rep 2:101–103CrossRef
3.
go back to reference Akyol O, Isci N, Temel I, Ozgocmen S, Uz E, Murat M, Buyukberber S (2001) The relationships between plasma and erythrocyte antioxidant enzymes and lipid peroxidation in patients with rheumatoid arthritis. Joint Bone Spine 68:311–317CrossRef Akyol O, Isci N, Temel I, Ozgocmen S, Uz E, Murat M, Buyukberber S (2001) The relationships between plasma and erythrocyte antioxidant enzymes and lipid peroxidation in patients with rheumatoid arthritis. Joint Bone Spine 68:311–317CrossRef
4.
go back to reference Ozgocmen S, Sogut S, Ardicoglu O, Fadillioglu E, Pekkutucu I, Akyol O (2004) Serum nitric oxide, catalase, superoxide dismutase, and malondialdehyde status in patients with ankylosing spondylitis. Rheumatol Int 24:80–83CrossRefPubMed Ozgocmen S, Sogut S, Ardicoglu O, Fadillioglu E, Pekkutucu I, Akyol O (2004) Serum nitric oxide, catalase, superoxide dismutase, and malondialdehyde status in patients with ankylosing spondylitis. Rheumatol Int 24:80–83CrossRefPubMed
5.
go back to reference Keenoy BM, Moorkens G, Vertommen J, Leeuw ID (2001) Antioxidant status and lipoprotein in chronic fatigue syndrome. Life Sci 68:2037–2049CrossRefPubMed Keenoy BM, Moorkens G, Vertommen J, Leeuw ID (2001) Antioxidant status and lipoprotein in chronic fatigue syndrome. Life Sci 68:2037–2049CrossRefPubMed
6.
go back to reference Vecchiet J, Capillone F, Falasca K, Mezzetti A, Pizzigallo E, Bucciarelli T, De Laurentis S, Affaitati G, De Cesare D, Giamberardino MA (2004) Relationship between musculoskeletal symptoms and blood markers of oxidative stress in patients with chronic fatigue syndrome. Neurosci Lett 335:151–154CrossRef Vecchiet J, Capillone F, Falasca K, Mezzetti A, Pizzigallo E, Bucciarelli T, De Laurentis S, Affaitati G, De Cesare D, Giamberardino MA (2004) Relationship between musculoskeletal symptoms and blood markers of oxidative stress in patients with chronic fatigue syndrome. Neurosci Lett 335:151–154CrossRef
7.
go back to reference Esterbauer H, Schaur RJ, Zollner H (1991) Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11:81–128CrossRefPubMed Esterbauer H, Schaur RJ, Zollner H (1991) Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11:81–128CrossRefPubMed
8.
go back to reference Sogut S, Zoroglu S, Ozyurt H, Yilmaz HR, Ozugurlu F, Sivasli E, Yetkin O, Yanik M, Tutkun H, Savas HA, Tarakcioglu M, Akyol O (2003) Changes in nitric oxide levels and antioxidant enzyme activities may have a role in the pathophysiological mechanisms involved in autism. Clin Chim Acta 331:111–117CrossRefPubMed Sogut S, Zoroglu S, Ozyurt H, Yilmaz HR, Ozugurlu F, Sivasli E, Yetkin O, Yanik M, Tutkun H, Savas HA, Tarakcioglu M, Akyol O (2003) Changes in nitric oxide levels and antioxidant enzyme activities may have a role in the pathophysiological mechanisms involved in autism. Clin Chim Acta 331:111–117CrossRefPubMed
9.
go back to reference Kigwell BA (2000) Nitric oxide-mediated metabolic regulation during exercise: effect of training in health and cardiovascular disease. FASEB J 14:1685–1696CrossRefPubMed Kigwell BA (2000) Nitric oxide-mediated metabolic regulation during exercise: effect of training in health and cardiovascular disease. FASEB J 14:1685–1696CrossRefPubMed
10.
go back to reference Akyol O, Zoroglu SS, Armutcu F, Sahin S, Gurel A (2004) Nitric oxide as a physiopathological factor in neuropsychiatric disorders. In Vivo 18:377–390PubMed Akyol O, Zoroglu SS, Armutcu F, Sahin S, Gurel A (2004) Nitric oxide as a physiopathological factor in neuropsychiatric disorders. In Vivo 18:377–390PubMed
11.
go back to reference Cepinskas G, Rui T, Kvietys PR (2002) Interaction between reactive oxygen metabolites and nitric oxide in oxidant tolerance. Free Radic Biol Med 33:433–440PubMedCrossRef Cepinskas G, Rui T, Kvietys PR (2002) Interaction between reactive oxygen metabolites and nitric oxide in oxidant tolerance. Free Radic Biol Med 33:433–440PubMedCrossRef
12.
go back to reference Larson AA, Giovengo SL, Russell IJ, Michalek JE (2000) Changes in the concentrations of amino acids in the cerebrospinal fluid that correlate with pain in patients with fibromyalgia: implications for nitric oxide pathways. Pain 87:201–211CrossRefPubMed Larson AA, Giovengo SL, Russell IJ, Michalek JE (2000) Changes in the concentrations of amino acids in the cerebrospinal fluid that correlate with pain in patients with fibromyalgia: implications for nitric oxide pathways. Pain 87:201–211CrossRefPubMed
13.
go back to reference Wolfe F, Smythe HA, Yunus MB, Bennet RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P (1990) The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Arthritis Rheum 33:160–172PubMedCrossRef Wolfe F, Smythe HA, Yunus MB, Bennet RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P (1990) The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Arthritis Rheum 33:160–172PubMedCrossRef
14.
go back to reference Catal SA, Erdem HR, Okumus M, Ozgocmen S, Yorgancioglu ZR (2000) The measurement of pain pressure threshold in patients with rheumatoid arthritis. Pain Clin 12:187–191CrossRef Catal SA, Erdem HR, Okumus M, Ozgocmen S, Yorgancioglu ZR (2000) The measurement of pain pressure threshold in patients with rheumatoid arthritis. Pain Clin 12:187–191CrossRef
15.
go back to reference Okifuji A, Turk DC, Sinclair D, Starz TW, Marcus DA (1997) A standardized manual tender point survey. I. Development and determination of a threshold point for the identification of positive tender points in fibromyalgia syndrome. J Rheumatol 24:377–383PubMed Okifuji A, Turk DC, Sinclair D, Starz TW, Marcus DA (1997) A standardized manual tender point survey. I. Development and determination of a threshold point for the identification of positive tender points in fibromyalgia syndrome. J Rheumatol 24:377–383PubMed
16.
go back to reference Ozgocmen S, Yoldas T, Kamanli A, Yildizhan H, Yigiter R, Ardicoglu O (2003) Auditory P300 event related potentials and serotonin reuptake inhibitor treatment in patients with fibromyalgia. Ann Rheum Dis 62:551–555CrossRefPubMed Ozgocmen S, Yoldas T, Kamanli A, Yildizhan H, Yigiter R, Ardicoglu O (2003) Auditory P300 event related potentials and serotonin reuptake inhibitor treatment in patients with fibromyalgia. Ann Rheum Dis 62:551–555CrossRefPubMed
17.
18.
go back to reference Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50–55PubMed Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50–55PubMed
19.
go back to reference Sarmer S, Ergin S, Yavuzer G (2000) The validity and reliability of the Turkish version of the Fibromyalgia Impact Questionnaire. Rheumatol Int 20:9–12CrossRefPubMed Sarmer S, Ergin S, Yavuzer G (2000) The validity and reliability of the Turkish version of the Fibromyalgia Impact Questionnaire. Rheumatol Int 20:9–12CrossRefPubMed
20.
go back to reference Esterbauer H, Cheeseman KH (1990) Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. In: Packer L, Glazer AN (eds) Oxygen radicals in biological systems, Methods Enzymol. Academic Press, California, 186:407–421 Esterbauer H, Cheeseman KH (1990) Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. In: Packer L, Glazer AN (eds) Oxygen radicals in biological systems, Methods Enzymol. Academic Press, California, 186:407–421
21.
go back to reference Cortas NK, Wakid NW (1990) Determination of inorganic nitrate in serum and urine by a kinetic cadmium-reduction method. Clin Chem 36:1440–1443PubMed Cortas NK, Wakid NW (1990) Determination of inorganic nitrate in serum and urine by a kinetic cadmium-reduction method. Clin Chem 36:1440–1443PubMed
22.
go back to reference Sun Y, Oberley LW, Li Y (1988) A simple method for clinical assay of superoxide dismutase. Clin Chem 34:497–500PubMed Sun Y, Oberley LW, Li Y (1988) A simple method for clinical assay of superoxide dismutase. Clin Chem 34:497–500PubMed
23.
go back to reference Prajda N, Weber G (1975) Malign transformation-linked imbalance: decreased XO activity in hepatomas. FEBS Lett 59:245–249CrossRefPubMed Prajda N, Weber G (1975) Malign transformation-linked imbalance: decreased XO activity in hepatomas. FEBS Lett 59:245–249CrossRefPubMed
24.
go back to reference Giusti G (1974) Adenosine deaminase. In: Bergmeyer MV (ed) Methods of enzymatic analysis, 2nd edn. Academic Press, New York, pp. 1092–1098 Giusti G (1974) Adenosine deaminase. In: Bergmeyer MV (ed) Methods of enzymatic analysis, 2nd edn. Academic Press, New York, pp. 1092–1098
25.
go back to reference Eisinger J, Gandolfo C, Zakarian H, Ayavou T (1997) Reactive oxygen species, antioxidant status and fibromyalgia. J Musculoskeletal Pain 5:5–15CrossRef Eisinger J, Gandolfo C, Zakarian H, Ayavou T (1997) Reactive oxygen species, antioxidant status and fibromyalgia. J Musculoskeletal Pain 5:5–15CrossRef
26.
go back to reference Lund N, Bengtsson A, Thorborg P (1986) Muscle oxygen tissue pressure in primary fibromyalgia. Scand J Rheumatol 15:165–173PubMedCrossRef Lund N, Bengtsson A, Thorborg P (1986) Muscle oxygen tissue pressure in primary fibromyalgia. Scand J Rheumatol 15:165–173PubMedCrossRef
27.
go back to reference Bennett RM, Clark SR, Goldberg L, Nelson D, Bonafede RP, Porter J, Specht D (1989) Aerobic fitness in patients with fibrositis. A controlled study of respiratory gas exchange and 133xenon clearance from exercising muscle. Arthritis Rheum 32:454–460PubMedCrossRef Bennett RM, Clark SR, Goldberg L, Nelson D, Bonafede RP, Porter J, Specht D (1989) Aerobic fitness in patients with fibrositis. A controlled study of respiratory gas exchange and 133xenon clearance from exercising muscle. Arthritis Rheum 32:454–460PubMedCrossRef
28.
go back to reference Hein G, Franke S (2002) Are advanced glycation end-product-modified proteins of pathogenetic importance in fibromyalgia? Rheumatology 41:1163–1167CrossRefPubMed Hein G, Franke S (2002) Are advanced glycation end-product-modified proteins of pathogenetic importance in fibromyalgia? Rheumatology 41:1163–1167CrossRefPubMed
29.
go back to reference Lindh MH, Johansson LG, Hedberg M, Henning GB, Grimby G (1995) Muscle fiber characteristics, capillaries and enzymes in patients with fibromyalgia and controls. Scand J Rheumatol 24:34–37PubMedCrossRef Lindh MH, Johansson LG, Hedberg M, Henning GB, Grimby G (1995) Muscle fiber characteristics, capillaries and enzymes in patients with fibromyalgia and controls. Scand J Rheumatol 24:34–37PubMedCrossRef
30.
go back to reference Jeschonneck M, Graohmann G, Hein G, Sprott H (2000) Abnormal microcirculation and temperature in skin above tender points in patients with fibromyalgia. Rheumatology 39:917–921CrossRefPubMed Jeschonneck M, Graohmann G, Hein G, Sprott H (2000) Abnormal microcirculation and temperature in skin above tender points in patients with fibromyalgia. Rheumatology 39:917–921CrossRefPubMed
31.
go back to reference Fulle S, Mecocci P, Fano G, Vecchiet I, Vecchini A, Racciotti D, Cherubini A, Pizzigallo E, Vecchiet L, Senin U, Beal MF (2000) Specific oxidative alterations in vastus lateralis muscle of patients with the diagnosis of chronic fatigue syndrome. Free Radic Biol Med 29:1252–1259CrossRefPubMed Fulle S, Mecocci P, Fano G, Vecchiet I, Vecchini A, Racciotti D, Cherubini A, Pizzigallo E, Vecchiet L, Senin U, Beal MF (2000) Specific oxidative alterations in vastus lateralis muscle of patients with the diagnosis of chronic fatigue syndrome. Free Radic Biol Med 29:1252–1259CrossRefPubMed
32.
go back to reference Sackner MA, Gummels EM, Adams JA (2004) Say NO to fibromyalgia and chronic fatigue syndrome: an alternative and complementary therapy to aerobic exercise. Med Hypotheses 63:118–123CrossRefPubMed Sackner MA, Gummels EM, Adams JA (2004) Say NO to fibromyalgia and chronic fatigue syndrome: an alternative and complementary therapy to aerobic exercise. Med Hypotheses 63:118–123CrossRefPubMed
33.
go back to reference Bagis S, Tamer L, Sahin G, Bilgin R, Guler H, Ercan B, Erdogan C (2005) Free radicals and antioxidants in primary fibromyalgia: an oxidative stress disorder? Rheumatol Int 25:188–190CrossRefPubMed Bagis S, Tamer L, Sahin G, Bilgin R, Guler H, Ercan B, Erdogan C (2005) Free radicals and antioxidants in primary fibromyalgia: an oxidative stress disorder? Rheumatol Int 25:188–190CrossRefPubMed
34.
go back to reference Bilici M, Efe H, Koroglu MA, Uydu HA, Bekaroglu M, Deger O (2001) Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord 64:43–51CrossRefPubMed Bilici M, Efe H, Koroglu MA, Uydu HA, Bekaroglu M, Deger O (2001) Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord 64:43–51CrossRefPubMed
35.
go back to reference Park DC, Glass JM, Minear M, Crofford LJ (2001) Cognitive function in fibromyalgia patients. Arthritis Rheum 44:2125–2133CrossRefPubMed Park DC, Glass JM, Minear M, Crofford LJ (2001) Cognitive function in fibromyalgia patients. Arthritis Rheum 44:2125–2133CrossRefPubMed
36.
go back to reference Delibas N, Ozcankaya R, Altuntas I (2002) Clinical importance of erythrocyte malondialdehyde levels as a marker of cognitive deterioration in patients with dementia of Alzheimer type: a repeated study in 5-year interval. Clin Biochem 32:137–141CrossRef Delibas N, Ozcankaya R, Altuntas I (2002) Clinical importance of erythrocyte malondialdehyde levels as a marker of cognitive deterioration in patients with dementia of Alzheimer type: a repeated study in 5-year interval. Clin Biochem 32:137–141CrossRef
37.
go back to reference Merchant RE, Carmack CA, Wise CM (2000) Nutritional supplementation with Chlorella pyrenoidosa for patients with fibromyalgia syndrome: a pilot study. Phytother Res 14:167–173CrossRefPubMed Merchant RE, Carmack CA, Wise CM (2000) Nutritional supplementation with Chlorella pyrenoidosa for patients with fibromyalgia syndrome: a pilot study. Phytother Res 14:167–173CrossRefPubMed
38.
go back to reference Ozgocmen S, Catal SA, Ardicoglu O, Kamanli A (2000) Effect of omega-3 fatty acids in the management of fibromyalgia syndrome. Int J Clin Pharmacol Ther 38:362–363PubMed Ozgocmen S, Catal SA, Ardicoglu O, Kamanli A (2000) Effect of omega-3 fatty acids in the management of fibromyalgia syndrome. Int J Clin Pharmacol Ther 38:362–363PubMed
39.
go back to reference Hostmark AT, Lystad E, Vellar OD, Hovi K, Berg JE (1993) Reduced plasma fibrinogen, serum peroxides, lipids, and apolipoproteins after a 3-week vegetarian diet. Plant Foods Hum Nutr 43:55–61CrossRefPubMed Hostmark AT, Lystad E, Vellar OD, Hovi K, Berg JE (1993) Reduced plasma fibrinogen, serum peroxides, lipids, and apolipoproteins after a 3-week vegetarian diet. Plant Foods Hum Nutr 43:55–61CrossRefPubMed
Metadata
Title
Antioxidant status, lipid peroxidation and nitric oxide in fibromyalgia: etiologic and therapeutic concerns
Authors
Salih Ozgocmen
Huseyin Ozyurt
Sadik Sogut
Omer Akyol
Ozge Ardicoglu
Hulya Yildizhan
Publication date
01-05-2006
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 7/2006
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-005-0079-y

Other articles of this Issue 7/2006

Rheumatology International 7/2006 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.